290 related articles for article (PubMed ID: 14530509)
1. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Baricos WH; Reed JC; Cortez SL
Exp Biol Med (Maywood); 2003 Oct; 228(9):1018-22. PubMed ID: 14530509
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells.
Baricos WH; Cortez SL; Deboisblanc M; Xin S
J Am Soc Nephrol; 1999 Apr; 10(4):790-5. PubMed ID: 10203363
[TBL] [Abstract][Full Text] [Related]
3. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.
Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB
Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023
[TBL] [Abstract][Full Text] [Related]
5. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
Huang Y; Border WA; Lawrence DA; Noble NA
Kidney Int; 2006 Aug; 70(3):515-22. PubMed ID: 16788698
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L
Kidney Int; 2005 Dec; 68(6):2651-66. PubMed ID: 16316341
[TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
[TBL] [Abstract][Full Text] [Related]
8. A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells.
Tada H; Tsukamoto M; Ishii H; Isogai S
Diabetes Res Clin Pract; 1994 May; 24(1):33-9. PubMed ID: 7924884
[TBL] [Abstract][Full Text] [Related]
9. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells.
Song CY; Kim BC; Hong HK; Kim BK; Kim YS; Lee HS
Am J Physiol Renal Physiol; 2002 Sep; 283(3):F423-30. PubMed ID: 12167592
[TBL] [Abstract][Full Text] [Related]
10. High glucose reduces generation of plasmin activity by mesangial cells.
Fisher EJ; McLennan SV; Yue DK; Turtle JR
Microvasc Res; 1997 Mar; 53(2):173-8. PubMed ID: 9143550
[TBL] [Abstract][Full Text] [Related]
11. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
13. Effects of uPA on mesangial matrix changes in the kidney of diabetic rats.
Cheng H; Chen C; Wang S
Ren Fail; 2014 Sep; 36(8):1322-7. PubMed ID: 25010090
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA
Kidney Int; 2005 Apr; 67(4):1297-307. PubMed ID: 15780082
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Niedbala MJ; Sartorelli AC
Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
[TBL] [Abstract][Full Text] [Related]
16. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
Bi Oh S; Suh N; Kim I; Lee JY
Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
[TBL] [Abstract][Full Text] [Related]
17. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
18. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
